Publications by authors named "Y Samyshkin"

Claim this Profile
C
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.
Shinsuke Iida, Yusuke Yasutomi, Yevgeniy Samyshkin, Yi-Chen Chen, Chi-Chang Chen

PLoS One· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.
Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, Eric M Maiese, Leah Sansbury

Value Health· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Domenica Lorusso, Holly Guy, Yevgeniy Samyshkin, Carol Hawkes, Kasey Estenson

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Andreas Nikolaou, Apoorva Ambavane, Anshul Shah, Wenkang Ma, Jon Tosh, Yevgeniy Samyshkin

Expert Rev Hematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Anshul Shah, Jonathan C Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin

Clinicoecon Outcomes Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis